LEGN logo

LEGN Legend Biotech Corporation

NASDAQ · Biotechnology · Healthcare

$15.25
-0.85 (-5.28%)

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multi…

Market Cap: $2.82Bwww.legendbiotech.com

Price

No data yet.

Social Signal Score

60
5d
—
30d
59
9 mentions
—
60d
60
11 mentions
—
90d
60
12 mentions
—
news: 9 · rss: 2 · 4chan: 1

Analyst Ratings

20 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 6Sell 0Strong Sell 0
Avg price target$61+300.0%
Low $40Median $65High $78
Current Consensus

Revenue

$359.50M+3476.05%
$10.05M$135.87M$261.68M$387.50M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-0.79
$-0.90–$-0.65
5 analysts
FY2026
$0.08
$-0.13–$0.19
3 analysts
FY2027
$0.49+494% YoY
$0.15–$0.69
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Alan S. Bash
Sector
Healthcare
Industry
Biotechnology
Employees
3,300
Beta
0.40
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
4.05
www.legendbiotech.com